Ocuphire Pharma Results Presentation Deck
17
Percent of Subjects With Improv. or Worsening in Binocular DRSS of ≥ 3-Steps
Potential Phase 3 Endpoints as an Oral Drug; Results Improve with Time
Percent of Subjects (%)
Percent of Subjects With Improvement or Worsening in
DRSS of ≥ 3 Steps From Baseline
Binocular Eyes
(mITT-LOCF) - Week 12
18%
16%
14%
12%
10%
8%
6%
4%
2%
0%
12%
p=0.07
0%
n=45
n=49
Subjects with >= 3 Steps Worsening
(observed)
Placebo (N=49)
p=0.61
4%
APX3330 (N=46)
7%
n=49 n=45
Subjects with >= 3 Step
Improvement (observed)
Percent of Subjects (%)
18%
16%
14%
12%
10%
8%
6%
4%
2%
0%
Percent of Subjects With Improvement or Worsening in
DRSS of ≥ 3 Steps From Baseline
Binocular Eyes
(mITT-LOCF) - Week 24
16%
p=0.04
p=0.38
6%
APX3330 (N=46)
11%
0%
n=49 n=45
n=49 n=45
Subjects with >= 3 Steps Worsening Subjects with >= 3 Step Improvement
(observed)
(observed)
Placebo (N=49)
Source: ZETA-1 Clinical Trial
Note: Large "N" indicates total number of participants within each arm for the mITT-LOCF population. Small "n" indicates total number of evaluable eyes for each respective endpoint and arm.
Note: Images from Central Reading Center will be reviewed prior to EOP2 FDA meeting
OcuphireView entire presentation